Completed PHASE3 INTERVENTIONAL 2-arm NCT03248037

Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation

Randomized, Double-masked, Placebo-controlled Evaluation of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation

Sponsor: Cornea Research Foundation of America

Conditions Bullous Keratopathy Fuchs' Endothelial Dystrophy

Interventions Netarsudil Placebo

Updated 9 times since 2017 Last updated: Jan 25, 2021 Started: Sep 5, 2017 Primary completion: Jul 9, 2019 Completion: Jul 9, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Bullous Keratopathy and Fuchs' Endothelial Dystrophy and is currently completed. Cornea Research Foundation of America leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Mar 2021 [monthly]

Completed PHASE3
Aug 2019 — Jan 2021 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed

▶ Show 4 earlier versions

Feb 2019 — Aug 2019 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jun 2018 — Feb 2019 [monthly]

Recruiting PHASE3
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2017 — Feb 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cornea Research Foundation of America

Data source: Cornea Research Foundation of America

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Indianapolis, United States